This case demonstrates that durable responses can occur upon retreatment with decitabine.
2
Clinical studies have demonstrated that decitabine has activity in patients with MDS.
3
The main adverse reaction of decitabine was myelosuppression, infection and so on.
4
Patients continued to receive decitabine until disease progression or an unacceptable adverse event occurred.
5
The clinical data of 12 MDS and AML patients treated with decitabine were analyzed retrospectively.
1
Inhibitors of DNA methylation such as 5-azacytidine or 5-azadeoxycytidine have been able to reverse DNA methylation patterns and have shown promise in patient studies.
1
Combination of 5-azadC and MeCP2 may be a promising treatment strategy for individuals with RA in which SFRP4 is inactivated.